Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Acrocephalosyndactylia 5Cholangiocarcinoma 4Neoplasm Metastasis 3Carcinoma, Transitional Cell 3Recurrence 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Eosinophilia 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 16Mitomycin 10Docetaxel 6BCG Vaccine 6erdafitinib 5durvalumab 4dodecyl maltoside 4Cystoscopy 4ALT-803 4Radiotherapy 25-aminolevulinic acid hexyl ester 2viscum album peptide 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1hydroxycamptothecinum 1enfortumab vedotin 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Surveys and Questionnaires 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Mitozytrex 1Maintenance 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × pemigatinib × 1 year × Clear all
NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
30 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡